Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR-IPR-15006810Phase 4Not yet recruiting
Phase 4, open-label trial of sufentanil and sevoflurane in None (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Blood adrenaline concentration, Blood noradrenaline concentration and 4 more. Planned start Aug 2015; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR-IPR-15006810.